Today: 9 June 2026
Browse Category

NASDAQ:QURE 24 September 2025 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure shares surged 34% to $14.27 in U.S. premarket trading Monday after news that FDA biologics chief Vinay Prasad will step down in April. The move follows a dispute over the agency’s demand for a new sham-surgery trial of uniQure’s Huntington’s gene therapy. The FDA has not agreed to approve the treatment based on current data. uniQure ended 2025 with $622.5 million in cash and investments.
9 March 2026
·
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?

uniQure shares plunged over 50% after the FDA said data for its Huntington’s disease gene therapy is not sufficient for approval, reversing earlier guidance. The stock dropped from about $68 to $34, wiping out roughly half its market value. Analysts called it a major regulatory setback, with some cutting price targets. Shareholder rights law firms launched investigations following the 57% one-day decline.
4 November 2025
·
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Early trial data show AMT-130 gene therapy slowed Huntington’s disease progression by 75% at 36 months in high-dose patients compared to controls. Treated participants’ neurofilament light levels dropped below baseline. The neurosurgical procedure lasts 12–20 hours. The developer plans a U.S. regulatory filing in 2026 if results hold.
26 September 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···

Stock Market Today

  • Microsoft Shares Drop 1.18% on June 8 Amid Mixed Technical Signals
    June 8, 2026, 9:25 PM EDT. Microsoft's stock declined 1.18% to $411.74 on June 8, 2026, amid mixed market signals. The share price fluctuated between $408.56 and $417.16 during the day, with volume dropping by 5 million shares to 30 million traded, easing risk as volume aligned with price movement. Despite a recent sell signal and short-term moving average negative outlook, Cowen & Co. maintained a 'Buy' rating on Microsoft with a short-term 'hold' action. Technical analysis indicates potential resistance at $433.70 and $421.13, but forecasts a 12.74% rise over three months with a 90% confidence interval between $448.27 and $523.89. Analysts see a weak near-term performance but view support around $407.78 as a buying opportunity, suggesting medium trading risk due to average volatility.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq rises after hours as chips recover

9 June 2026
Nasdaq jumped 0.86% as chip stocks rebounded, with Intel soaring 11.2% on news Google ordered over 3 million AI chips for 2028, while Apple slid 1.9% after unveiling new AI features. Investors await Wednesday’s May CPI inflation report, which could spark volatility in tech and growth stocks.
Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Go toTop